The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis

References

• Chahine EB, Kelley D, Childs-Kean LM. Sofosbuvir/velpatasvir/voxilaprevir: a pan-genotypic direct-acting antiviral combination for hepatitis C. Ann Pharmacother. 2018;52(4):352–363.
   PubMed Web of Science ®Google Scholar
• Llaneras J, Riveiro-Barciela M, Lens S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol. 2019;71:666–672.
   PubMed Web of Science ®Google Scholar
• Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146.
   PubMed Web of Science ®Google Scholar
• Heo YA, Deeks ED. Sofosbuvir/velpatasvir/voxilaprevir: a review in chronic hepatitis C. Drugs. 2018;78(5):577–587.
   PubMed Web of Science ®Google Scholar
• Hammerstad SS, Grock SF, Lee HJ, et al. Diabetes and hepatitis C: a two-way association. Front Endocrinol. 2015;6:134.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Pozzi M, Dassano A, et al. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. Acta Diabetol. 2019;56(3):341–354.
   PubMed Web of Science ®Google Scholar
• Niccum BA, Stine JG, Wynter JA, et al. Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes. Clin Diabetes. 2020;38(1):40–46.
   PubMedGoogle Scholar
• Hammer HF, Högenauer C. Lactose intolerance and malabsorption. UpToDate. [Published 2021 Oct 21; cited 2021 Dec 21]. Available from: https://www.uptodate.com/contents/lactose-intolerance-and-malabsorption-clinical-manifestations-diagnosis-and-management
   Google Scholar
• Doyle MA, Cooper C. Successful hepatitis C antiviral therapy induces remission of type 2 diabetes: a case report. Am J Case Rep. 2015;16:745–750.
   PubMedGoogle Scholar
• Ribaldone DG, Sacco M, Saracco GM. The effect of viral clearance achieved by direct-acting antiviral agents on hepatitis C virus positive patients with type 2 diabetes mellitus: a word of caution after the initial enthusiasm. J Clin Med. 2020;9:563.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Desbois AC, Comarmond C, et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67(11):2025–2034.
   PubMed Web of Science ®Google Scholar
• Sacco M, Saracco GM. The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C. Minerva Gastroenterol. 2021;67(3):264–272.
   Google Scholar
• Pavone P, Tieghi T, d‘Ettorre G, et al. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016;22(5):462.e1–462.e3.
   PubMed Web of Science ®Google Scholar
• Yuan M, Zhou J, Du L, et al. Hepatitis C virus clearance with glucose improvement and factors affecting the glucose control in chronic hepatitis C patients. Sci Rep. 2020;10(1):1976.
   PubMed Web of Science ®Google Scholar
• Zied HY, Abo Alnasr NM, El-Bendary AS, et al. Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4. Diabetes Metab Syndr. 2020;14(4):679–682.
   PubMed Web of Science ®Google Scholar
• Lapumnuaypol K, Pisarcik D, Putthapiban P, et al. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: a systematic review & meta-analysis. Indian J Med Res. 2020;152(6):562–567.
   PubMed Web of Science ®Google Scholar
• Ciancio A, Bosio R, Bo S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 2018;90(2):320–327.
   PubMed Web of Science ®Google Scholar
• Russo FP, Zanetto A, Gambato M, et al. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. J Viral Hepat. 2020;27(2):188–194.
   PubMed Web of Science ®Google Scholar
• Gualerzi A, Bellan M, Smirne C, et al. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents. PLOS One. 2018;13(12):e0209216.
   PubMed Web of Science ®Google Scholar
• Andres J, Barros M, Arutunian M, et al. Treatment of hepatitis C virus and long-term effect on glycemic control. J Manag Care Spec Pharm. 2020;26(6):775–781.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Nakahara T, Kogiso T, et al. Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: a multicenter study. JGH Open. 2021;5(2):228–234.
   PubMed Web of Science ®Google Scholar
• Government of Canada. Summary safety review – direct-acting antivirals (DAAs) – Health Canada; 2020 Feb 17 [cited 2022 Jan 10]. Available from: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00234
   Google Scholar
• GOV.UK. Drug safety update: direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes – GOV.UK. [Published 2018 Dec 18; cited 2021 Dec 21]. Available from: https://www.gov.uk/drug-safety-update/direct-acting-antivirals-for-chronic-hepatitis-c-risk-of-hypoglycaemia-in-patients-with-diabetes#report-any-suspected-adverse-drug-reactions
   Google Scholar
• Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–122.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.
   PubMed Web of Science ®Google Scholar
• ICH. Introductory guide MedDRA version 24.1. Published online September 2021. Available from: https://www.meddra.org/how-to-use/support-documentation/english
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Reau N, Hinestrosa F, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial. Gastroenterology. 2016;151:893.e1–901.e1.
   Web of Science ®Google Scholar
• Gane EJ, Schwabe C, Hyland RH, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with hepatitis C virus genotype 1 or 3 infections. Gastroenterology. 2016;151:448.e1–456.e1.
   Web of Science ®Google Scholar
• Lawitz E, Poordad F, Wells J, et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral–experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017;65:1803–1809.
   PubMed Web of Science ®Google Scholar
• US Food and Drug. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. Accessed Aug 28, 2019 [cited 2021 May 12]. Available from:https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and
   Google Scholar
• Asselah T, Shafran SD, Bourgeois S, et al. Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection. J Viral Hepat. 2019;26(10):1229–1232.
   PubMed Web of Science ®Google Scholar
• Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87–95.
   PubMed Web of Science ®Google Scholar
• Izumi N, Takehara T, Chayama K, et al. Sofosbuvir–velpatasvir plus ribavirin in japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int. 2018;12(4):356–367.
   PubMed Web of Science ®Google Scholar
• Inabu Y, Saegusa A, Inouchi K, et al. Plasma concentrations of glucagon-like peptide 1 and 2 in calves fed calf starters containing lactose. J Dairy Sci. 2017;100(11):9361–9371.
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Masarone M, Peta V, et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol. 2014;20(41):15233–15240.
   PubMed Web of Science ®Google Scholar
• Abdelkader RY, Abdelrazek MA, Attallah A, et al. High blood glucose levels are associated with fibrosis/cirrhosis progression in chronic hepatitis C. J Immunoassay Immunochem. 2021;42(6):559–570.
   PubMedGoogle Scholar
• Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol. 2021;27(11):1006–1021.
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Petta S, Fracanzani AL, et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study. Diabetes Obes Metab. 2020;22(12):2408–2416.
   PubMed Web of Science ®Google Scholar
• Aziz K, Khan M, Shahbaz A, et al. Treatment of hepatitis C with sofosbuvir, velpatasvir and voxilaprevir decreases hemoglobin A1c and dependence on anti-glycemic medications. BJSTR. 2018;9.
   Google Scholar
• Wilson E, Covert E, Hoffmann J, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). J Hepatol. 2019;71(3):498–504.
   PubMed Web of Science ®Google Scholar
• Collins LF, Adekunle RO, Cartwright EJ. Metabolic syndrome in HIV/HCV co-infected patients. Curr Treat Options Infect Dis. 2019;11(4):351–371.
   PubMedGoogle Scholar
• Mocroft A, Lundgren JD, Rockstroh JK, EuroSIDA study, et al. Influence of hepatitis C coinfection and treatment on risk of diabetes mellitus in HIV-positive persons. Open Forum Infect Dis. 2020;7(12):ofaa470.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao YR, Liu HL, et al. Insulin resistance predicts virological response to interferon-α in chronic hepatitis B patients. J Clin Gastroenterol. 2016;50(6):506–512.
   PubMed Web of Science ®Google Scholar
• Ciancio A, Ribaldone DG, Dotta A, et al. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. Liver Int. 2021;41(2):276–287.
   PubMed Web of Science ®Google Scholar
• Li J, Gordon SC, Rupp LB, et al. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int. 2019;39:1027–1032.
   PubMed Web of Science ®Google Scholar
• Weidner P, Boettche D, Zimmerer T, et al. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2018;27(3):281–289.
   PubMed Web of Science ®Google Scholar
• Cacciola I, Russo G, Filomia R, et al. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int. 2021;41(9):2059–2067.
   PubMed Web of Science ®Google Scholar
• ElBadry MM, Ali DA, Eltaweel NH, et al. Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control. Egypt Liver J. 2020;10:1–7.
   Google Scholar
• Hussein HA, Allam AS, Moaty ASA. Evaluation of glycated haemoglobin (HbA1c) level in type 2 diabetic chronic HCV non-cirrhotic treatment-naïve egyptian patients eradicated with sofosbuvir plus daclatasvir. Curr Diabetes Rev. 2020;16(2):165–170.
   PubMed Web of Science ®Google Scholar
• Jain A, Kalra BS, Srivastava S, et al. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients. Indian J Gastroenterol. 2019;38(1):39–43.
   PubMed Web of Science ®Google Scholar
• Ikeda A, Ikeda K, Takai A, et al. Hepatitis C treatment with sofosbuvir and ledipasvir accompanied by immediate improvement in hemoglobin A1c. Digestion. 2017;96(4):228–230.
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Nevola R, Guerrera B, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33(7):1379–1382.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–576.
   PubMed Web of Science ®Google Scholar
• Delgado-Borrego A, Jordan SH, Negre B, Halt-C Trial Group, et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8(5):458–462.
   PubMed Web of Science ®Google Scholar
• Zhang W, Rao HY, Feng B, et al. Effects of interferon-alpha treatment on the incidence of hyperglycemia in chronic hepatitis C patients: a systematic review and meta-analysis. PLOS One. 2012;7(6):e39272.
   PubMed Web of Science ®Google Scholar
• Butt AA, Umbleja T, Andersen JW, et al. ACTG A5178 study team. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in hepatitis C virus/HIV-coinfected persons: the AIDS clinical trials group A5178 study. Clin Infect Dis. 2012;55:631–638.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1. Gut. 2012;61(10):1473–1480.
   PubMed Web of Science ®Google Scholar
• Strauhs-Nitsch L, Campiolo MF, Morsoletto DBG, et al. Curing hepatitis C with the new direct acting antivirals did not improve insulin resistance after one year. Arq Gastroenterol. 2020;57(3):267–271.
   PubMedGoogle Scholar